Axel Merseburger, MD, PhD

home / authors / axel-merseburger-md-phd

Articles

Merseburger Discusses Future Research of PRESIDE Trial Enzalutamide Combo

Merseburger Discusses Future Research of PRESIDE Trial Enzalutamide Combo

Axel Merseburger, MD, PhD
March 23rd 2022

Axel Merseburger, MD, PhD, spoke about implementing the treatment combination of enzalutamide plus docetaxel/prednisone for progressive castration-resistant prostate cancer from the PRESIDE trial into the real-world.

Merseburger Reflects on Data Presented at 2022 ASCO GU in Prostate Cancer

Merseburger Reflects on Data Presented at 2022 ASCO GU in Prostate Cancer

Axel Merseburger, MD, PhD
March 14th 2022

Axel Merseburger, MD, PhD, looked back on 2022 ASCO GU and the new data presented for the treatment of prostate cancer.

Merseburger Offers PRESIDE Trial Overview of Continuous Enzalutamide in mCRPC

Merseburger Offers PRESIDE Trial Overview of Continuous Enzalutamide in mCRPC

Axel Merseburger, MD, PhD
February 23rd 2022

Axel Merseburger, MD, PhD, spoke key results of the PRESIDE trial, which examined continuous enzalutamide to treat patients with metastatic castration-resistant prostate cancer and progressive disease.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
17-Year-Old Girl at 13 Weeks Gestation Presents With Vaginal Bleeding & Cramping
Published: February 13th 2015 | Updated: July 27th 2025
17-Year-Old Girl at 13 Weeks Gestation Presents With Vaginal Bleeding & Cramping